ArticleFrontiers in immunology2025
Case Report: Anti-ADAM23 antibody: an overlooked autoantibody against VGKC-complex in autoimmune encephalitis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Antibodies against voltage-gated potassium channel (VGKC) complexes include anti-LGI1 and anti-CASPR2. Anti-ADAM23 antibodies have not been previously reported in autoimmune encephalitis (AE). Case report: We report a 71-year-old female patient who presented with rapidly progressive short-term memory loss, psychobehavioural abnormalities, and impaired consciousness. Six months earlier, she had recovered from herpes simplex encephalitis (HSE). Cerebrospinal fluid (CSF) analysis suggested lymphocytic inflammation. AE was considered after the exclusion of HSV reactivation and other infectious etiologies. A comprehensive screening for commercially available autoimmune and paraneoplastic antibodies yielded negative results. A tissue-based assay (TBA) of CSF revealed a pattern of neuropil reactivity (neuropil pattern, suggesting the presence of neuronal surface antibodies (NS-Ab). A laboratory-developed antibody panel screening using a cell-based assay (CBA) identified an anti-ADAM23 antibody. Immunofluorescence staining showed that ADAM23 colocalized with Tuj1, which is expressed on the surface of neurons. Subclass analysis revealed that the anti-ADAM23 antibody predominantly belonged to the IgG4 subclass. Finally, the patient was diagnosed with an anti-ADAM23 antibody-associated AE. During the early stages of the disease, the patient underwent several courses of intravenous immunoglobulin (IVIg) with limited efficacy. Following the addition of high-dose methylprednisolone pulse therapy, the patient's consciousness improved from coma to stupor and the seizures were relieved. Conclusion: We propose that anti-ADAM23 antibody, a previously overlooked autoantibody targeting the VGKC complex, may have diagnostic significance for autoimmune encephalitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.